The DOI matches its Crossref record; 313 of the 313 references it cites were found in a registry or an index.
Hypoxic microenvironment in cancer: role in metabolic reprogramming
Open accessAbstract
Hypoxia, a defining hallmark of solid tumors, arises from structurally and functionally abnormal vasculature, rapid cellular proliferation, and impaired perfusion, resulting in chronic and cycling oxygen deprivation within the tumor massThe hypoxic tumor microenvironment orchestrates extensive molecular reprogramming primarily through stabilization and activation of hypoxia-inducible factors (HIF-1α and HIF-2α), which regulate broad transcriptional networks governing metabolism, angiogenesis, stemness, invasion, and immune modulation. Under low oxygen tension, tumor cells shift toward aerobic glycolysis, enhance glutamine utilization, promote lipid synthesis and storage, suppress mitochondrial oxidative phosphorylation, and fine-tune redox balance through coordinated regulation of ROS-generating and antioxidant systems. These adaptations not only sustain proliferation and survival under metabolic stress but also facilitate epithelial–mesenchymal transition, extracellular matrix remodeling, and metastatic dissemination. Beyond malignant cells, hypoxia reprograms stromal compartments—including cancer-associated fibroblasts, endothelial cells, tumor-associated macrophages, and myeloid-derived suppressor cells—thereby establishing a metabolically cooperative, angiogenic, and profoundly immunosuppressive microenvironment. Hypoxia-induced acidosis, lactate accumulation, and HIF-driven cytokine signaling further impair cytotoxic T-cell and NK-cell activity, contributing to immune escape and resistance to radiotherapy, chemotherapy, and immunotherapy. Emerging evidence from single-cell multi-omics, spatial transcriptomics, metabolic imaging, and early-phase clinical trials targeting HIF signaling, angiogenic pathways, and metabolic enzymes has uncovered actionable vulnerabilities in hypoxia-driven malignancies. This review synthesizes the mechanistic foundations of hypoxia-induced metabolic reprogramming, its role in tumor progression and therapeutic resistance, and discusses innovative strategies aimed at exploiting hypoxia-associated metabolic dependencies to advance precision oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As tumors grow beyond the reach of blood vessels, hypoxia leads to the stabilization of hypoxia-inducible factor 1α (HIF-1α), which then induces the expression of vascular endothelial growth factor (VEGF) and promotes angiogenesis [54].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–313 of 313
Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies
Ciepła, J., & Smolarczyk, R. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01501-1 · Cited by 81
Zhang, C., Yang, C., Feldman, M. J., Wang, H., Pang, Y., Maggio, D. M., Zhu, D., Nesvick, C. L., Dmitriev, P., Bullova, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18125 · Cited by 80
Hypoxia induces a lipogenic cancer cell phenotype via HIF1α-dependent and -independent pathways
Valli, A., Rodriguez, M., Moutsianas, L., Fischer, R., Fedele, V., Huang, H.-L., Van Stiphout, R., Jones, D., Mccarthy, M., Vinaxia, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3058 · Cited by 79
McKeage, M. J., Gu, Y., Wilson, W. R., Hill, A. M., Amies, K., Melink, T. J., & Jameson, M. B. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-432 · Cited by 77
Manafi‐Farid, R., Askari, E., Shiri, I., Pirich, C., Asadi, M., Khateri, M., Zaidi, H., & Beheshti, M. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.04.004 · Cited by 76
Targeting Hypoxia-Driven Metabolic Reprogramming to Constrain Tumor Progression and Metastasis
Galvis, M. M., & Teng, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155487 · Cited by 73
Kirito, K., Hu, Y., & Komatsu, N. (2009) · Cell Cycle · doi:10.4161/cc.8.17.9544 · Cited by 73
Cutsem, E. V., Lenz, H., Furuse, J., Tabernero, J. M., Heinemann, V., Ioka, T., Bazin, I. S., Ueno, M., Csőszi, T., Wasan, H. S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.4007 · Cited by 73
RNA interference for HIF-1α inhibits its downstream signalling and affects cellular proliferation
Hänze, J., Eul, B. G., Savai, R., Krick, S., Goyal, P., Grimminger, F., Seeger, W., & Rose, F. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.10.153 · Cited by 72
The influence of endothelial metabolic reprogramming on the tumor microenvironment
Kane, K. M., Edwards, D. N., & Chen, J. (2024) · Oncogene · doi:10.1038/s41388-024-03228-5 · Cited by 72
Chabowski, A., Górski, J., Calles-Escandón, J., Tandon, N. N., & Bonen, A. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.05.045 · Cited by 68
Visualizing vasculature and its response to therapy in the tumor microenvironment
Lin, Q., Choyke, P. L., & Sato, N. (2023) · Theranostics · doi:10.7150/thno.84947 · Cited by 68
Targeting fatty acid oxidation enhances response to HER2-targeted therapy
Nandi, I., Ji, L., Smith, H. W., Avizonis, D. Z., Papavasiliou, V., Lavoie, C. A., Pacis, A., Attalla, S. S., Sanguin‐Gendreau, V., & Muller, W. J. (2024) · Nature Communications · doi:10.1038/s41467-024-50998-3 · Cited by 68
Advancements in pathology: Digital transformation, precision medicine, and beyond
Ahuja, S., & Zaheer, S. (2024) · Journal of Pathology Informatics · doi:10.1016/j.jpi.2024.100408 · Cited by 68
Self-citationProlyl hydroxylase domain enzymes: important regulators of cancer metabolism
Pollard, P. J., Yang, M. H., Su, H., Soga, T., & Kranc, K. R. (2014) · Hypoxia · doi:10.2147/hp.s47968 · Cited by 66
Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion
Hilmi, M., Nicolle, R., Bousquet, C., & Neuzillet, C. (2020) · Cancers · doi:10.3390/cancers12102969 · Cited by 66
Cheng, X., Peng, T., Chu, T., Yang, Y., Liu, J., Gao, Q., Cao, C., & Wei, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01722-1 · Cited by 66
Zhou, X., Guo, X., Chen, M., Xie, C., & Jiang, J. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0256 · Cited by 65
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Powell, S. F., Mazurczak, M. A., Dib, E. G., Bleeker, J. S., Geeraerts, L., Tinguely, M., Lohr, M. M., McGraw, S. C., Jensen, A. W., Ellison, C. A., et al. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01235-5 · Cited by 63
Targeting bromodomain and extraterminal proteins in breast cancer
Sahni, J. M., & Keri, R. A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.015 · Cited by 61
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective
Xiao, Y., Li, Y., & Zhao, H. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02113-9 · Cited by 61
Falchook, G. S., Wheler, J. J., Naing, A., Jackson, E. F., Jankú, F., Hong, D. S., Ng, C. S., Tannir, N. M., Lawhorn, K., Huang, M., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2163 · Cited by 59
HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
Maccallini, C., Ammazzalorso, A., Filippis, B. D., Fantacuzzi, M., Giampietro, L., & Amoroso, R. (2022) · Pharmaceuticals · doi:10.3390/ph15060667 · Cited by 59
Han, J. H., Lee, E., Park, W., Ha, K., & Chung, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1275000 · Cited by 59
Sabit, H., Arneth, B. M., Pawlik, T. M., Abdel-Ghany, S. E., Ghazy, A., Abdelazeem, R. M., Alqosaibi, A. I., Al-Dhuayan, I. S., Almulhim, J., Alrabiah, N. A., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18010075 · Cited by 59
Pharmacological or genetic inhibition of LDHA reverses tumor progression of pediatric osteosarcoma
Gao, S., Tu, D.-N., Li, H., Jiang, J., Cao, X., You, J.-B., & Zhou, X. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.04.029 · Cited by 58
Hypoxia signaling: Challenges and opportunities for cancer therapy
Ivan, M., Fishel, M. L., Tudoran, O. M., Pollok, K. E., Wu, X., & Smith, P. J. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.10.002 · Cited by 57
Papadopoulos, K. P., Goel, S., Beeram, M., Wong, A., Desai, K. K., Haigentz, M., Milián, M. L., Mani, S., Tolcher, A. W., Lalani, A. S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0483 · Cited by 55
Dichloroacetate and metformin synergistically suppress the growth of ovarian cancer cells
Li, B., Li, X., Ni, Z., Zhang, Y., Zeng, Y., Yan, X., Huang, Y., He, J., Lyu, X., Wu, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10694 · Cited by 55
FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells
Rellinger, E. J., Craig, B. T., Alvarez, A. L., Dusek, H. L., Kim, K. W., Qiao, J., & Chung, D. H. (2016) · Surgery · doi:10.1016/j.surg.2016.09.009 · Cited by 55
Joshi, M., Kim, J., D’Alessandro, A., Monk, E., Bruce, K., Elajaili, H., Nozik-Grayck, E., Goodspeed, A., Costello, J. C., & Schlaepfer, I. R. (2020) · Cancers · doi:10.3390/cancers12113431 · Cited by 54
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
Foehrenbacher, A., Patel, K., Abbattista, M. R., Guise, C. P., Secomb, T. W., Wilson, W. R., & Hicks, K. O. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00263 · Cited by 54
Choi, H. J., Song, B. J., Gong, Y., Gwak, W. J., & Soh, Y. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.70 · Cited by 54
Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases
Kumar, M. A., Baba, S. K., Khan, I. R., Khan, M. S., Husain, F. M., Ahmad, S., Haris, M., Singh, M., Akil, A. A., Macha, M. A., et al. (2025) · MedComm · doi:10.1002/mco2.70120 · Cited by 52
Mizuno, T., Nagao, M., Yamada, Y., Narikiyo, M., Ueno, M., Miyagishi, M., Taira, K., & Nakajima, Y. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700871 · Cited by 49
Interaction between AhR and HIF-1 signaling pathways mediated by ARNT/HIF-1β
Zhang, M., Hu, Y., Yang, F., Zhang, J., Zhang, J., Yu, W., Wang, M., Lv, X., Li, J., Bai, T., et al. (2022) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-022-00564-8 · Cited by 48
The future of MRI in radiation therapy: Challenges and opportunities for the MR community
Goodburn, R. J., Philippens, M. E. P., Lefebvre, T. L., Khalifa, A., Bruijnen, T., Freedman, J. N., Waddington, D. E. J., Younus, E., Aliotta, E., Meliadò, G., et al. (2022) · Magnetic Resonance in Medicine · doi:10.1002/mrm.29450 · Cited by 48
Multhoff, G., & Vaupel, P. W. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00598-0 · Cited by 48
Jariwala, N. H., Mehta, G. A., Bhatt, V. D., Hussein, S., Parker, K. A., Yunus, N., Parker, J. S., Guo, J. Y., & Gatza, M. L. (2021) · NAR Cancer · doi:10.1093/narcan/zcab035 · Cited by 46
Glutamine metabolism in cancers: Targeting the oxidative homeostasis
Gong, T., Zheng, C., Ou, X., Zheng, J., Yu, J., Chen, S., Duan, Y., & Liu, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.994672 · Cited by 45
Jóźwiak, P., Krześlak, A., Pomorski, L., & Lipińska, A. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.969 · Cited by 43
Ahuja, S., & Zaheer, S. (2025) · Immunology · doi:10.1111/imm.70045 · Cited by 43
Self-citationTransforming growth factor-β signaling: from tumor microenvironment to anticancer therapy
Chan, M. K., Chan, E. L.-Y., Ji, Z. Z., Chan, A. S. W., Li, C., Leung, K. T., To, K., & Tang, P. M. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00137 · Cited by 42
Fu, Y., Yi, Y., Shao, Y., Jiang, J., & Deng, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561388 · Cited by 42
Kunachowicz, D., Tomecka, P., Sędzik, M., Kalinin, J., Kuźnicki, J., & Rembiałkowska, N. (2025) · Cells · doi:10.3390/cells14141057 · Cited by 42
Le, Q., McCoy, J., Williamson, S. K., Ryu, J. K., Gaspar, L. E., Edelman, M. J., Dakhil, S. R., Sides, S. D., Crowley, J. J., & Gandara, D. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0436 · Cited by 42
Metabolic Relationship Between Cancer-Associated Fibroblasts and Cancer Cells
Sazeides, C., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_14 · Cited by 41
Cao, D., Yang, J., Deng, Y., Su, M., Wang, Y., Feng, X., Xiong, Y., Bai, E., Duan, Y., & Huang, Y. P. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01099-4 · Cited by 41
Strowd, R. E., III, Ellingson, B. M., Raymond, C., Yao, J., Wen, P. Y., Ahluwalia, M. S., Piotrowski, A. F., Desai, A. S., Clarke, J. L., Lieberman, F. S., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04456-7 · Cited by 40
Wang, Z., Zhu, M., Dong, R., Cao, D., Li, Y., Chen, Z., Cai, J., & Zuo, X. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02203-8 · Cited by 40
Basheeruddin, M., & Qausain, S. (2024) · Cureus · doi:10.7759/cureus.70700 · Cited by 40
Choueiri, T. K., Merchan, J. R., Figlin, R. A., McDermott, D. F., Arrowsmith, E. R., Michaelson, M. D., Tykodi, S. S., Heath, E. I., Spigel, D. R., D'souza, A., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00649-1 · Cited by 39
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma
Abou‐Alfa, G. K., Chan, S. L., Lin, C., Chiorean, E. G., Holcombe, R. F., Mulcahy, M. F., Carter, W. D., Patel, K., Wilson, W. R., Melink, T. J., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1671-3 · Cited by 39
Development and pre-clinical testing of a novel hypoxia-activated KDAC inhibitor
Skwarska, A., Calder, E. D. D., Sneddon, D., Bolland, H. R., Odyniec, M. L., Mistry, I. N., Martin, J., Folkes, L. K., Conway, S. J., & Hammond, E. M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.004 · Cited by 38
Jaśkiewicz, M., Moszyńska, A., Serocki, M., Króliczewski, J., Bartoszewska, S., Collawn, J. F., & Bartoszewski, R. (2022) · IfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmund · doi:10.17179/excli2021-4622 · Cited by 37
Lipid-mediated regulation of the cancer-immune crosstalk
Ma, Y., Zhang, S., Jin, Z., & Shi, M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105131 · Cited by 36
Zhang, T., Lv, Q., & Jin, W. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189137 · Cited by 36
Advances in the mechanisms of HIF-1α-enhanced tumor glycolysis and its relation to dedifferentiation
Zeng, Y., Tao, Y., Du, G., Huang, T., Chen, S., Fan, L., & Zhang, N. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.05.003 · Cited by 35
Ezzeddini, R., Taghikhani, M., Farrokhi, A. S., Somi, M. H., Samadi, N., Esfahani, A., & Rasaee, M. J. (2021) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-021-00791-3 · Cited by 34
Effects of glycolysis on the polarization and function of tumor‑associated macrophages (Review)
Cao, J., Zeng, F., Liao, S., Cao, L., & Zhou, Y. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5518 · Cited by 34
Hao, Y.-H., Zhu, W., Li, J., Lin, R., Huang, W., Ain, Q. U., Liu, K., Wei, N., Cheng, D., Wu, Y., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.026 · Cited by 34
Hypoxia Activated Prodrugs: Factors Influencing Design and Development
Liang, D., Miller, G., & Tranmer, G. K. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666151021111016 · Cited by 33
Acidity‐mediated induction of FoxP3 + regulatory T cells
Rao, D., Stunnenberg, J. A., Lacroix, R., Dimitriadis, P., Kaplon, J., Verburg, F., van Royen, P. T., Hoefsmit, E. P., Renner, K., Blank, C. U., et al. (2023) · European Journal of Immunology · doi:10.1002/eji.202250258 · Cited by 33
Ahuja, S., & Zaheer, S. (2023) · Cell Biology International · doi:10.1002/cbin.12097 · Cited by 33
Self-citationChoueiri, T. K., Powles, T. B., Voss, M. H., Plimack, E. R., Gurney, H., Song, Y., Perini, R. F., Rodriguez-Lopez, K., & Rini, B. I. (2023) · Future Oncology · doi:10.2217/fon-2023-0283 · Cited by 33
Belzutifan for the treatment of renal cell carcinoma
Wu, X., Lazris, D., Wong, R. L., & Tykodi, S. S. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251317846 · Cited by 33
Abi‐Jaoudeh, N., Dayyani, F., Chen, P., Fernando, D. M., Fidelman, N. A., Javan, H., Liang, P., Hwang, J.-I., & Imagawa, D. K. (2021) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s304275 · Cited by 31
Central role of hypoxia-inducible factor-1α in metabolic reprogramming of cancer cells: A review
Zhu, B., Cheng, L., Huang, B., Liu, R., & Ren, B. (2024) · Medicine · doi:10.1097/md.0000000000040273 · Cited by 31
Covens, A. L., Blessing, J. A., Bender, D., Mannel, R. S., & Morgan, M. A. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.09.032 · Cited by 31
Liu, Q., Fan, D., Adah, D., Wu, Z., Liu, R., Yan, Q., Zhang, Y., Du, Z., Wang, D., Li, Y., et al. (2018) · Oncology Reports · doi:10.3892/or.2018.6667 · Cited by 31
Pharmacological effect and mechanism of orlistat in anti-tumor therapy: A review
Hao, X., Zhu, X., Tian, H., Lai, G., Zhang, W., Zhou, H., & Liu, S. (2023) · Medicine · doi:10.1097/md.0000000000034671 · Cited by 30
Defining hypoxia in cancer: A landmark evaluation of hypoxia gene expression signatures
Giovannantonio, M. D., Hartley, F., Elshenawy, B., Barberis, A., Hudson, D., Shafique, H. S., Allott, V. E. S., Harris, D. A., Lord, S., Haider, S. A., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.100764 · Cited by 30
In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds
Hamilton (2010) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s11795 · Cited by 29
Silencing of HIF-1α suppresses tumorigenicity of renal cell carcinoma through induction of apoptosis
Xu, K., Ding, Q., Fang, Z., Zheng, J., Gao, P.-F., Lu, Y., & Zhang, Y. (2009) · Cancer Gene Therapy · doi:10.1038/cgt.2009.66 · Cited by 28
Oh, J. E., Jung, B. H., Park, J., Kang, S., & Lee, H. (2020) · Cells · doi:10.3390/cells9112447 · Cited by 28
Erdem, A., Kaye, S., Caligiore, F., Johanns, M., Leguay, F., Schuringa, J. J., Ito, K., Bommer, G. T., & van Gastel, N. (2025) · Cancer & Metabolism · doi:10.1186/s40170-025-00392-4 · Cited by 28
Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers
Ajnai, G., Cheng, C., Kan, T.-C., Lu, J., Rahayu, S., Chiu, A., & Chang, J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040847 · Cited by 28
Ahuja, S., Sureka, N., & Zaheer, S. (2024) · Apmis · doi:10.1111/apm.13447 · Cited by 26
Self-citationAcidity promotes the differentiation of immunosuppressive regulatory T cells
Tuomela, K., & Levings, M. K. (2023) · European Journal of Immunology · doi:10.1002/eji.202350511 · Cited by 26
Xu, Y., Xia, D., Huang, K., & Liang, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04872-x · Cited by 26
Recent advancements in single-cell metabolic analysis for pharmacological research
Hou, Y., Yao, H., & Lin, J. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.08.014 · Cited by 25
Introducing urea into tirapazamine derivatives to enhance anticancer therapy
Xu, Y., Lv, J., Kong, C., Liu, Y., Wang, K., Tang, Z., & Chen, X. (2024) · National Science Review · doi:10.1093/nsr/nwae038 · Cited by 25
Exploring monocarboxylate transporter inhibition for cancer treatment
Koltai, T., & Fliegel, L. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00210 · Cited by 25
ChatGPT as an aid for pathological diagnosis of cancer
Malik, S., & Zaheer, S. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154989 · Cited by 22
Self-citationRedefining the role of hypoxia-inducible factors (HIFs) in oxygen homeostasis
Arias, C. F., Acosta, F. J., Bertocchini, F., & Fernández-Arias, C. (2025) · Communications Biology · doi:10.1038/s42003-025-07896-1 · Cited by 22
Yap, T. A., Dumbrava, E. E. I., Rodon, J. A., Hong, D. S., Pant, S., Karp, D. D., Piha-Paul, S. A., Subbiah, V., Tsimberidou, A. M., Fu, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.3001 · Cited by 22
Jonker, P. B., & Muir, A. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050814 · Cited by 21
Exploiting metabolic vulnerabilities in cancer: From mechanisms to therapeutic opportunities
Xue, Z.-R., Xin, Y.-Y., & Jin, W. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218067 · Cited by 21
Efficacy and comparative effectiveness of sirolimus as an anticancer drug
Hu, M., Ekshyyan, O. Y., Ferdinandez, L. H., Rong, X., Caldito, G. C., & Nathan, C. O. (2011) · The Laryngoscope · doi:10.1002/lary.21724 · Cited by 19
McDermott, A., & Tavassoli, A. (2024) · Transcription · doi:10.1080/21541264.2024.2417475 · Cited by 18
Villareal, L., Falcon, D. M., Xie, L., & Xue, X. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02699-3 · Cited by 17
Multi-level interaction between HIF and AHR transcriptional pathways in kidney carcinoma
Lafleur, V. N., Halim, S., Choudhry, H., Ratcliffe, P. J., & Mole, D. R. (2023) · Life Science Alliance · doi:10.26508/lsa.202201756 · Cited by 16
Understanding the relationship between cancer associated cachexia and hypoxia-inducible factor-1
Muthamil, S., Kim, H. Y., Jang, H., Lyu, J., Shin, U. C., Go, Y., Park, S., Lee, H. G., & Park, J. H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114802 · Cited by 16
Hypoxia-Induced Changes in Endothelial Cell Phenotype and Function
Tóth, A., & Jeney, V. (2025) · Antioxidants and Redox Signaling · doi:10.1089/ars.2025.1022 · Cited by 14
Use of Radiomics in Characterizing Tumor Hypoxia
Huang, M., Law, H., & Tam, S. Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146679 · Cited by 14
Kim, S. H., Hwang, D., Park, H., Yang, E. G., Chung, H. S., & Kim, S. Y. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.06.017 · Cited by 13
Regulatory T Cells in Tumor Microenvironment: Therapeutic Approaches and Clinical Implications
Sureka, N., & Zaheer, S. (2025) · Cell Biology International · doi:10.1002/cbin.70031 · Cited by 13
Self-citationAlteration of Lipid Metabolism in Hypoxic Cancer Cells
Gonzalez, G. A., Osuji, E., Fiur, N. C., Clark, M. G., Ma, S., Lukov, L. L., & Zhang, C. (2024) · Chemical & Biomedical Imaging · doi:10.1021/cbmi.4c00050 · Cited by 12
Pandey, S., Singh, R., Habib, N., Tripathi, R., Kushwaha, R., & Mahdi, A. A. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.4.1121 · Cited by 11
Zhao, L., Tan, L., Wu, Q., Fu, C., Ren, X., Ren, J., Wang, Z., Zhang, J., & Meng, X. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.12.149 · Cited by 11
A Fatty Acid Synthase Inhibitor Shows New Anticancer Mechanisms
Bueno, M. J., & Colomer, R. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.08.023 · Cited by 10
Wei, L., Yuan, N., Chen, Y., & Gong, P. (2021) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.23889 · Cited by 10
When fat goes down, prostate cancer is on the ropes
Zadra, G., & Loda, M. F. (2019) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1595308 · Cited by 9
The role of hypoxia-inducible factor-3α in human disease
López-Mejía, A., Briseño-Díaz, P., & Robles‐Flores, M. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2025.120007 · Cited by 9
Unlocking new frontiers: novel immune targets for next-generation cancer immunotherapy
Zaheer, S., & Sureka, N. (2025) · Korean Journal of Clinical Oncology · doi:10.14216/kjco.24322 · Cited by 8
Self-citationGastelum, G., Poteshkina, A., Veena, M. S., Artiga, E., Weckstein, G., & Frost, P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188438 · Cited by 6
Du, J., Chu-ting, Z., Li, T., & Li, Y. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i12.1371 · Cited by 6
Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas.
Furman, R. R., Bartlett, N. L., Wong, A., McCulloch, L. M., Lam, G. N., Rosenthal, T. M., Flinn, I. W., & Leonard, J. P. (2006) · Blood · doi:10.1182/blood.v108.11.2429.2429 · Cited by 6
Nishii, K., Ohashi, K., Watanabe, H., Makimoto, G., Nakasuka, T., Higo, H., Ninomiya, K., Kato, Y., Kubo, T., Rai, K., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.12900 · Cited by 5
Hypoxia-activated KDAC inhibitor: Taking a breath from untargeted therapy
Staudt, M., & Jung, M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.08.016 · Cited by 5
Park, S., Lee, N., & Jeong, C. (2023) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2024.28.1.83 · Cited by 4
Shi, R., Sun, J., Zhou, H., Hu, T., Gao, Z., Wang, X., Li, M., Zhou, Z., & Shu, Y. (2024) · Journal Of Big Data · doi:10.1186/s40537-024-00945-2 · Cited by 4
Flagged first, then by citations
Research works printed but not linked: 8
- Calorini, 2012, Extracellular acidity as favouring factor of tumor progression and metastatic dissemination, Exp Oncol, 34, 79
- Gao, 2015, Acidic extracellular microenvironment promotes the invasion and cathepsin B secretion of PC-3 cells, Int J Clin Exp Med, 8
- Jarc, 2019, Lipid droplets and the management of cellular stress, Yale J Biol Med, 92
- Leek, 2002, Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in Human breast cancer, Cancer Res, 62
- Boucher, 1990, Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy, Cancer Res, 50
- Zhang, 2025, Systematic and comprehensive insights into HIF-1 stabilization under normoxic conditions: implications for cellular adaptation and therapeutic strategies in cancer, Cell Mol Biol Lett, 30, 10.1186/s11658-024-00682-7 · DOI
- Han, 2023, Natural compounds as lactate dehydrogenase inhibitors: potential therapeutics for lactate dehydrogenase inhibitors-related diseases, Front Pharmacol, 14, 10.3389/fphar.2023.1275000 · DOI
- Hay, 2003, Structure-activity relationships of 1, 2, 4-benzotriazine 1, 4-dioxides as hypoxia-selective analogues of tirapazamine, J Med Chem, 46, 10.1021/jm020367 · DOI
Cited by
Sorted by citations
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“As tumors grow beyond the reach of blood vessels, hypoxia leads to the stabilization of hypoxia-inducible factor 1 α (HIF-1 α ), which then induces the expression of vascular endothelial growth factor (VEGF) and promotes angiogenesis [54].”
Glycolytic reprogramming and the EMT drive cervical cancer progression via the NQO1/HIF1α-SIX1 axis
Zhu, G., Piao, Z., Gao, Y., Cong, X., Wei, P., Han, A., Zhou, H., Lin, Z., & Jin, T. (2026) · iScience · doi:10.1016/j.isci.2026.117007 · Cited by 1
Hammouz, R. Y., Maciejek, K., & Bednarek, A. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156740
Chronobiology of Cancer: How Aging Fuels Oncogenesis at the Molecular Level
Singh, A., Misra, A., & Zaheer, S. (2026) · Aging and Cancer · doi:10.1002/aac2.70027
Self-citationLi, X., Yang, K., Liang, X., Qi, F., & Lv, Y. (2026) · Precision medicine and engineering. · doi:10.1016/j.preme.2026.100085
Metadata
- Authors
- Sureka, N., Maheshwari, R., Agravat, A., Singhal, S., Zaman, S., Rishi, B., Siraj, F., Zaheer, S., & Misra, A.
- Affiliations
- Safdarjang Hospital (IN)
- Department of Pathology, Pandit Deendayal Upadhyay (PDU) Medical College
- Indian Council of Medical Research (IN)
- National Institute of Child Health (PK)
- Corresponding author
- Zaheer, Sufian
- Misra, Aroonima
- ORCID
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2026-03-31
- Volume
- 16
- Pages
- 1771365-1771365
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC13076347
- OpenAlex
- W7143706570
- Cited by
- 11
- References
- 313
- Citations by year
- 2026: 11
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor hypoxia, hypoxic tumor microenvironment, metabolic reprogramming, hypoxia-inducible factor, HIF-1α, HIF-2α, aerobic glycolysis, glutamine metabolism, lipid metabolism, redox homeostasis, reactive oxygen species, epithelial-mesenchymal transition, extracellular matrix remodeling, metastasis, cancer-associated fibroblasts, tumor-associated macrophages, myeloid-derived suppressor cells, tumor immunosuppression, immune evasion, treatment resistance, HIF-targeted therapy, precision oncology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
